The National Health Insurance Administration's Pharmaceutical Price and Bidding and Procurement Guidance Center announced the list of pharmaceutical companies rated as "particularly serious" and "serious" as of March 31, 2024, and three new pharmaceutical companies were added in this period. Visual China | fig
policy
[Guarding the "medical money" of the masses, the national flight inspection carried out "looking back" for the first time]
On April 28, 2024, the official website of the National Health Insurance Administration announced that the National Health Insurance Administration, together with the Ministry of Finance, the National Health Commission, and the State Administration of Traditional Chinese Medicine, issued the "2024 Medical Security Fund Unannounced Inspection Work Plan".
The national unannounced inspection will be carried out in the mode of "national organization, provincial crossing, and territorial cooperation", which will achieve full coverage of all provinces in the country and further increase the scope of random inspection cities. In principle, the number of cities to be inspected in each province has been increased from one to two per province per year, of which all provincial capitals must be checked. Each province will simultaneously inspect a certain number of public designated medical institutions, private designated medical institutions and designated retail pharmacies.
In 2024, a national flight inspection "look back" will be carried out for the first time. In the five provinces randomly selected, a certain proportion of the designated medical institutions that have been unannounced in previous years were selected for unannounced inspections. Avoid institutions that have already been checked that they will not be checked again in a few years, and have slack ideas in regulating the use of medical insurance funds.
Focus on five aspects of designated medical institutions: First, focus on the fields of critical medicine, anesthesia, lung tumors, etc., investigate and deal with the illegal use of medical insurance funds, and focus on investigating and dealing with fraud and insurance fraud. The second is to focus on cardiovascular medicine, orthopedics, blood purification, rehabilitation, medical imaging, clinical testing and other areas that have been key to inspection and self-examination and self-correction in previous years, and check whether they are self-inspected and rectified as required. The third is to focus on whether the problems found in the previous annual inspection still exist and whether the rectification is in place. The fourth is to focus on the online procurement of drug consumables, focusing on whether public medical institutions purchase all the required drug consumables on the provincial centralized procurement platform in accordance with the regulations. Fifth, for patients who are admitted to other provinces and places for medical treatment, check whether there is any illegal use of medical insurance funds.
Jianyan: Since the establishment of the unannounced inspection mechanism by the National Health Insurance Bureau in 2019, in the past five years, the National Health Insurance Administration has successively organized more than 200 inspection teams, randomly inspected nearly 500 designated medical institutions nationwide, and the national and provincial unannounced inspections have recovered more than 8 billion yuan of medical insurance-related funds. On the one hand, unannounced inspections have produced a positive effect of cracking down on fraud and insurance fraud, correcting violations of laws and regulations, recovering the losses of the medical insurance fund, and strengthening high-pressure deterrence, and has become a "sharp sword" to protect the safety of the medical insurance fund. On the other hand, unannounced inspections have also guided designated institutions to strengthen internal management and standardize the use of funds as active awareness and conscious actions.
[The State Food and Drug Administration issued the "Measures for the Administration of Cosmetics Inspection"]
On April 29, 2024, the website of the State Food and Drug Administration issued the "Announcement on the Issuance of the Administrative Measures for the Inspection of Cosmetics". According to the nature and purpose of the inspection, cosmetics inspection is divided into licensing inspection, routine inspection, cause inspection and other inspection. Depending on the manner of inspection, cosmetics inspections are divided into on-site inspections and off-site inspections. On-site inspection is the main way to inspect cosmetics. The Measures for the Administration of Cosmetics Inspection will come into force on November 1, 2024.
Jianyan: The 2024 CCTV "3.15" party exposed the chaos of cosmetics in the field of medical beauty, and some injections that promote various effects such as whitening, wrinkle removal, and weight loss did not even have cosmetics recorded, and finally hit consumers' faces. The promulgation of the Administrative Measures for Cosmetics Inspection will further standardize the inspection of cosmetics, protect the rights of consumers, effectively rectify the chaos in the industry, and promote the healthy development of the industry.
[The National Health Insurance Administration announced the list of "particularly serious" and "serious" untrustworthy pharmaceutical companies]
On April 30, 2024, the National Health Insurance Administration's Pharmaceutical Price and Bidding and Procurement Guidance Center announced the list of pharmaceutical companies rated as "particularly serious" and "serious" as of March 31, 2024 in various provinces The dishonest companies are: Changchun Zheren Pharmaceutical Distribution Co., Ltd. and Wuhan Wuyuan Biotechnology Co., Ltd. As a result, the list of "particularly serious" and "serious" enterprises has increased to 25.
The credit rating of price procurement is mainly determined based on the severity of the amount of bribes, unfair price behavior, and disruption of the order of centralized procurement. For example, a single bribe of more than 10,000 yuan is considered "average", a single bribe of more than 100,000 yuan is considered "moderate", a single bribe of more than 300,000 yuan is considered "serious", and a single bribe of more than 2 million yuan is "particularly serious".
Based on the credit rating of the pharmaceutical enterprise, measures such as reminding and admonishing the enterprise, reminding the risk, disclosing information on untrustworthiness, and even restricting or suspending the enterprise's involvement in the case or all drugs and medical consumables are on the network, bidding or distribution qualifications. For example, for "serious" rated enterprises, measures such as canceling the qualifications of the products involved in the case are taken to be disposed of, and for "particularly serious" rated enterprises, measures such as canceling the qualifications of all their products are to be put on the network and distributed.
Screenshot of the official website of the National Health Insurance Administration
Anti-rot
[Zhou Jun, the former chairman of Shanghai Pharmaceutical, was prosecuted]
The Supreme People's Procuratorate reported on April 30, 2024 that a few days ago, Zhou Jun, the former president of Shanghai Industrial (Group) Co., Ltd., was suspected of embezzlement and bribery, and the Second Branch of the Shanghai Municipal People's Procuratorate filed a public prosecution with the Shanghai Second Intermediate People's Court in accordance with the law. Zhou Jun served as the chairman of Shanghai Pharmaceutical from October 2016 to November 2023.
Previous
[Brain-Computer Interface Chinese Expert Consensus Released]
At the Zhongguancun Forum on Brain-Computer Interface Innovation Development and Application Forum held on April 26, 2024, the "Chinese Expert Consensus on the Implementation and Management of Clinical Research on Brain-Computer Interface for Nervous System Diseases" was released. Brain-computer interfaces are the creation of a direct connection between the human brain and an external device, which in turn enables direct communication between the brain and the computer.
Zhao Jizong, an academician of the Chinese Academy of Sciences, said at the forum that a consensus should be formulated so that researchers can better invest in the research and development of brain-computer interfaces in the mainland, and at the same time protect the interests of patients, so that the implementation of clinical research can be safer and more scientific. This will play an important role in promoting the clinical application of the continental brain-computer interface, especially the clinical application of implantable brain-computer interface technology.
Jianyan: Recently, brain-computer interface has attracted much attention in the medical field, and new breakthroughs have been made one after another. At present, there are still many diseases that have no cure or rehabilitation, such as paraplegia caused by spinal cord injury, quadriplegia, and a large number of epilepsy, Parkinson's disease, etc., through brain-computer interface technology, the introduction of new artificial intelligence methods, may make breakthroughs in the future to respond to the needs of patients.
Medicines
[A new breakthrough in chronic limb ischemia, Abbott absorbable stent has been approved by the FDA]
On April 29, 2024, Abbott announced that its Esprit BTK Absorbable Stent System (Esprit BTK System) has received official approval from the U.S. Food and Drug Administration (FDA). This system is designed to completely dissolve the artery after it has been kept open and to deliver everolimus to promote vascular healing before it is completely dissolved.
This technique is a boon for patients with chronic limb ischemia (CLTI). Peripheral arterial disease is a common condition in which blood flow to the upper and lower extremities is reduced due to narrowing of the arteries. Patients with peripheral arterial disease (PAD) have insufficient blood supply to the upper and lower extremities (commonly found in the lower extremities) to meet the body's needs, while chronic limb ischemia (CLTI) is a more serious form of peripheral arterial disease (PAD) that severely impairs limb blood flow and microcirculation, resulting in resting pain, ischemic ulcers, and gangrene.
Jianyan: The treatment technology for chronic limb ischemia (CLTI) has been very limited, and the emergence of new technologies will become a new option for the treatment of this disease.
[The first domestic ROS1 lung cancer targeted drug anectinib was approved for marketing]
On April 30, 2024, CP Tianqing Pharmaceutical Group announced that its Category 1 new drug Anectinib (TQ-B3101/Unecritinib) has received marketing approval from the National Medical Products Administration (NMPA) of China. This approval marks an important step forward for the treatment of ROS1-positive non-small cell lung cancer (NSCLC) with domestic targeted drugs.
Anecutinib is a small molecule inhibitor specifically targeting ROS1/ALK/c-Met tyrosine kinases. It can selectively inhibit the in vitro proliferation of ROS1-positive, ALK-positive, and c-Met tumor cells, induce cell cycle arrest in G1 phase, and induce apoptosis, thereby exerting potent anti-tumor effects.
capital
【诺华以超17亿美元收购Mariana Oncology，扩展放射性配体疗法管线】
On May 3, 2024, Novartis announced on its website that it had entered into an acquisition agreement with Mariana Oncology. The acquisition of Mariana Oncology, a pre-clinical-stage biotechnology company focused on the development of novel radioligand therapies (RLTs), strengthens Novartis' RLT pipeline and expands the company's research infrastructure and clinical supply capabilities. Under the agreement, Novartis will make an upfront payment of $1 billion and potentially a further $750 million in milestone payments.
Southern Weekly reporter Song Bingchen
Editor-in-charge: Cao Haidong